ストックスクリーナーアプリを入手
24.58
2.31%
-0.58
アフターアワーズ：
24.58
前日終値:
$25.16
開ける：
$25.19
24時間の取引高:
492.89K
Relative Volume:
1.33
時価総額：
$744.67M
収益：
$344.23M
当期純損益:
$-24.16M
株価収益率:
-29.02
EPS:
-0.8471
ネットキャッシュフロー:
$28.33M
1週間 パフォーマンス:
+0.86%
1か月 パフォーマンス:
-1.68%
6か月 パフォーマンス:
+5.04%
1年 パフォーマンス:
+16.27%
1日の値動き範囲:
$24.37
$25.71
1週間の範囲:
$24.14
$25.71
52週間の値動き範囲:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
名前
Castle Biosciences Inc
セクター
電話
866-788-9007
住所
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
24.58 | 762.25M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
524.57 | 195.48B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
194.54 | 138.36B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.01 | 46.31B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
122.09 | 34.18B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
335.23 | 32.95B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-04-30 | 開始されました | Lake Street | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | BTIG Research | Buy |
| 2019-08-19 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-19 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Castle Biosciences Inc (CSTL) 最新ニュース
Castle Biosciences to present melanoma test data at conferences By Investing.com - Investing.com Canada
New data suggest some early melanomas carry higher relapse risk - Stock Titan
Laboratory teams drive progress in skin cancer diagnostics at Castle Biosciences - Traders Union
CSTL Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus
(CSTL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 - Sahm
Castle Biosciences inks expansion at Nova Place - WPXI
Castle Biosciences inks expansion at Nova Place on North SidePittsburgh Business Times - The Business Journals
Aug EndMonth: How sensitive is Castle Biosciences Inc to inflationShare Buyback & AI Enhanced Trading Signals - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Shares Down 7%What's Next? - MarketBeat
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - Bitget
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences CEO sells shares worth $246,195 By Investing.com - Investing.com Australia
Breakouts Watch: Does Castle Biosciences Inc have declining or rising EPSEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Ideas Watch: Can Castle Biosciences Inc deliver alphaWeekly Trade Report & AI Forecasted Stock Moves - baoquankhu1.vn
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock - MarketBeat
Castle Biosciences CEO sells shares worth $246,195 - Investing.com
Castle Biosciences (CSTL) CEO pre-planned sale of 9,836 shares after option exercise - Stock Titan
Strong 2025 revenue and governance focus in Castle Biosciences (CSTL) proxy - Stock Titan
Castle Biosciences, Inc. (CSTL) stock price, news, quote and history - Yahoo Finance Singapore
Castle Biosciences, Inc. (CSTL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AI Stocks: Can Castle Biosciences Inc maintain its current growth rate2026 Highlights & Daily Price Action Insights - baoquankhu1.vn
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) - Yahoo Finance
CSTL PE Ratio & Valuation, Is CSTL Overvalued - Intellectia AI
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Castle Biosciences CEO Maetzold sells shares worth $106,598 By Investing.com - Investing.com South Africa
Castle Biosciences CEO Maetzold sells shares worth $106,598 - Investing.com
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options - Stock Titan
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs - Stock Titan
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha
(CSTL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Castle Biosciences presents melanoma test data at AAD meeting By Investing.com - Investing.com Australia
Castle Biosciences Study Shows DecisionDx-Melanoma Test Enhances Risk Prediction Within AJCC Staging System - geneonline.com
Castle Biosciences presents melanoma test data at AAD meeting - investing.com
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Newswise
Castle test splits same-stage melanoma patients by 5-year survival odds - Stock Titan
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Bitget
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL) - Stock Titan
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL) - Stock Titan
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Hedge Fund Moves: Can Castle Biosciences Inc deliver alpha2026 Top Decliners & High Return Trade Opportunity Guides - baoquankhu1.vn
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - MarketBeat
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE StudySlideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha
Castle Biosciences Inc DecisionDx-Melanoma Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Valuation Update: Whats next for Castle Biosciences Inc stock2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Breakout Watch: Can Castle Biosciences Inc maintain its current growth rateMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
What are the future prospects of Castle Biosciences IncWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Castle Biosciences Inc (CSTL) 財務データ
収益
当期純利益
現金流量
EPS
1.57%
0.03%
大文字化:
|
ボリューム (24 時間):